Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / HOXA9



This biomarker is also known as:
  • ABD-B,
  • homeobox protein Hox-A9,
  • homeobox A9,
  • HOX1,
  • homeobox protein Hox-1G,
  • HOX1G,
  • homeo box A9,
  • P31269,
  • homeodomain protein HOXA9,
  • HOX1.7,
  • Homeobox protein Hox-1G,

View in BioMuta


HOXA9 is a sequence-specific transcription factor. It is a member of the homeobox gene family. These transcription factors are spatially and temporally regulated during embryonic development. HOXA9 is part of the A cluster on chromosome 7 and encodes a DNA-binding transcription factor which may regulate gene expression, morphogenesis, and differentiation. Read-through transcription exists between this gene and the upstream homeobox A10 (HOXA10) gene.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…

Head & neck, NOS


Phase: One
QA State: Curated


HOXA9 and NID2 have been identified as novel differentially methylated genes in oral squamous cell carcinoma. These genes were also shown to have significantly higher methylation levels in tumor than normal oral mucosa, as seen by ROC analysis of head and neck squamous cell carcinoma samples.

Performance Comment

HOXA9 and NID2 are promising oral squamous cell carcinoma biomarkers that should be studied on tissue, saliva and serum from larger cohorts. HOXA9 and NID2 were chosen for further study because they were the only candidate genes that had an AUC value equal to or higher than 0.75, and 100% specificity and sensitivity higher than 70%.



Phase: Two
QA State: Under Review


DNA methylation of HOXA9 has been found to be associated with ovarian cancer.

Performance Comment

HOXA9 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. HOXA9 was not in the group of 13 selected for further validation.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.